1-溴-2-氯-4-硝基苯 | 29682-39-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-2-氯-4-硝基苯
• 中文别名: 1-溴-2-氯-4-硝基苯,4-溴-3-氯硝基苯；3-氯-4-溴硝基苯
• 英文名称: 1-bromo-2-chloro-4-nitrobenzene
• 英文别名: 2-chloro-4-nitrobromobenzene
• CAS: 29682-39-1
• 化学式: C₆H₃BrClNO₂
• mdl: MFCD00051514
• 分子量: 236.452
• InChiKey: YKSXEJZFIQAUHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  59-62°C
• 沸点：
  282.2±20.0 °C(Predicted)
• 密度：
  1.827±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38,R33
• 海关编码：
  2904909090
• 包装等级：
  III
• 危险品运输编号：
  UN 2811
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器密封保存，并存放在阴凉干燥处。同时，确保工作环境有足够的通风或排气设施。

反应信息

• 作为反应物：
  描述：

  1-溴-2-氯-4-硝基苯 在 caesium carbonate 、 tin(ll) chloride 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 3-氯-4-苯氧基苯胺
  参考文献：
  名称：

  Discovery and Structure–Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG)

  摘要：

  The metabolism of poly(ADP-ribose) (PAR) in response to DNA strand breaks, which involves the concerted activities of poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribose) glycohydrolase (PARG), modulates cell recovery or cell death depending upon the level of DNA damage. While PARP inhibitors show high promise in clinical trials because of their low toxicity and selectivity for BRCA related cancers, evaluation of the therapeutic potential of PARG is limited by the lack of well-validated cell permeable inhibitors. In this study, target-related affinity profiling (TRAP), an alternative to high-throughput screening, was used to identify a number of druglike compounds from several chemical classes that demonstrated PARG inhibition in the low-micromolar range. A number of analogues of one of the most active chemotypes were synthesized to explore the structure activity relationship (SAR) for that series. This led to the discovery of a putative pharmacophore for PARG inhibition that contains a modified salicylanilide structure. Interestingly, these compounds also inhibit PARP-1, indicating strong homology in the active sites of PARG and PARP-1 and raising a new challenge for development of PARG specific inhibitors. The cellular activity of a lead inhibitor was demonstrated by the inhibition of both PARP and PARG activity in squamous cell carcinoma cells, although preferential inhibition of PARG relative to PARP was observed. The ability of inhibitors to modulate PAR metabolism via simultaneous effects on PARPs and PARG may represent a new approach for therapeutic development.

  DOI：

  10.1021/jm200325s
• 作为产物：
  描述：

  3,4-二氯硝基苯 在 乙醇 、 氨 作用下， 生成 1-溴-2-氯-4-硝基苯
  参考文献：
  名称：

  Koerner; Contardi, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1913, vol. <5> 22 I, p. 823

  摘要：

  DOI：

文献信息

• AZOLE INHIBITORS OF CYTOKINE PRODUCTION
  申请人：——

  公开号：US20010044445A1

  公开（公告）日：2001-11-22

  Compounds having the formula 1 are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors.

  具有以下化学式的化合物对于治疗由白细胞介素-2、白细胞介素-4或白细胞介素-5产生抑制剂预防或改善的疾病是有用的。
• Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors
  作者：Huiping Zhao、Gaurav Garg、Jinbo Zhao、Elisabetta Moroni、Antwan Girgis、Lucas S. Franco、Swapnil Singh、Giorgio Colombo、Brian S.J. Blagg

  DOI：10.1016/j.ejmech.2014.10.034

  日期：2015.1

  discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor. Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors. Structure–activity

  Hsp90 C端功能的调节代表了一种有前途的治疗方法，用于治疗癌症和神经退行性疾病。目前针对Hsp90 C末端抑制的药物发现工作集中在新霉素（一种转化为Hsp90抑制剂的抗生素）上。根据在开发新霉素衍生物和进行分子对接研究期间获得的结构信息，将含有联苯部分代替新霉素中存在的香豆素环的支架鉴定为新的Hsp90 C末端抑制剂。结构-活性关系研究产生了新的衍生物，它们以纳摩尔浓度抑制乳腺癌细胞系的增殖，这直接与Hsp90抑制作用相对应。
• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• 1-Aryl-3,3-dialkyltriazenes: A Convenient Synthesis from Dry Arenediazonium o-Benzenedisulfonimides - A High Yield Break Down to the Starting Dry Salts and Efficient Conversions to Aryl Iodides, Bromides and Chlorides
  作者：Margherita Barbero、Iacopo Degani、Nicola Diulgheroff、Stefano Dughera、Rita Fochi

  DOI：10.1055/s-2001-18072

  日期：——

  Synthesis 2001, No. 14, 26 1

  综合 2001, No. 14, 26 1
• Design, synthesis and evaluation of tetrahydrocarbazole derivatives as potential hypoglycemic agents
  作者：Li-Li Wang、Yao Du、Shu-Min Li、Fei Cheng、Na-Na Zhang、Rui Chen、Xing Cui、Sheng-Gang Yang、Ling-Ling Fan、Jian-Ta Wang、Bing Guo、Hao-Shu Wu、Ji-Quan Zhang、Lei Tang

  DOI：10.1016/j.bioorg.2021.105172

  日期：2021.10

  Aza-tetrahydrocarbazole compound 12b showed the most potent hypoglycemic activity with a 45% increase in glucose consumption when compared to the solvent control, which had approximately 1.2-fold higher activity than the positive control compounds (metformin and ZG02). An investigation of the potential mechanism indicated that 12b may exhibit hypoglycemic activity via activation of the AMPK pathway. Metabolic

  基于 ZG02 设计和合成了两个系列的四氢咔唑衍生物，ZG02 是我们之前研究中开发的有前景的候选物。在 HepG2 细胞系中筛选新制备的化合物的葡萄糖消耗活性。氮杂-四氢咔唑化合物12b显示出最有效的降血糖活性，与溶剂对照相比，葡萄糖消耗增加了 45%，其活性比阳性对照化合物（二甲双胍和 ZG02）高约 1.2 倍。对潜在机制的研究表明，12b可能通过激活 AMPK 途径表现出降血糖活性。代谢稳定性分析表明，12b在来自 SD 大鼠的人造胃肠液和血浆中均显示出良好的稳定性。进行了口服葡萄糖耐量试验 (OGTT)，结果进一步证实12b是一种有效的降血糖药。